Outcome of myelodysplastic neoplasms with unrelated donor transplants by donor type (univariable)
| Variables . | MUD . | MMUD . | P value . |
|---|---|---|---|
| Patient number | 672 | 288 | |
| 5-y OS (95% CI) | 54% (50-58) | 44% (38-51) | .005 |
| 5-y PFS (95% CI) | 48% (44-52) | 40% (34-46) | .016 |
| 5-y relapse/progression (95% CI) | 25% (21-28) | 24% (19-29) | .7 |
| 5-y NRM (95% CI) | 27% (24-31) | 36% (30-41) | .005 |
| D100 aGVHD (95% CI) | |||
| aGVHD grade 2-4 | 27% (24-31) | 31% (26-36) | .3 |
| aGVHD grade 3-4 | 11% (9-13) | 15% (11-19) | .09 |
| 5-y cGVHD (95% CI) | |||
| All | 39% (36-43) | 33% (27-39) | .07 |
| Mild | 14% (11-16) | 10% (6-14) | .14 |
| Moderate | 12% (9-14) | 7% (4-10) | .0034 |
| Severe | 8% (6-10) | 6% (15-25) | .4 |
| 5-y cGVHD-free survival (95% CI) | 21% (18-24) | 20% (15-25) | .6 |
| 5-y GRFS (95% CI) | 33% (29-37) | 29% (23-35) | .1 |
| Variables . | MUD . | MMUD . | P value . |
|---|---|---|---|
| Patient number | 672 | 288 | |
| 5-y OS (95% CI) | 54% (50-58) | 44% (38-51) | .005 |
| 5-y PFS (95% CI) | 48% (44-52) | 40% (34-46) | .016 |
| 5-y relapse/progression (95% CI) | 25% (21-28) | 24% (19-29) | .7 |
| 5-y NRM (95% CI) | 27% (24-31) | 36% (30-41) | .005 |
| D100 aGVHD (95% CI) | |||
| aGVHD grade 2-4 | 27% (24-31) | 31% (26-36) | .3 |
| aGVHD grade 3-4 | 11% (9-13) | 15% (11-19) | .09 |
| 5-y cGVHD (95% CI) | |||
| All | 39% (36-43) | 33% (27-39) | .07 |
| Mild | 14% (11-16) | 10% (6-14) | .14 |
| Moderate | 12% (9-14) | 7% (4-10) | .0034 |
| Severe | 8% (6-10) | 6% (15-25) | .4 |
| 5-y cGVHD-free survival (95% CI) | 21% (18-24) | 20% (15-25) | .6 |
| 5-y GRFS (95% CI) | 33% (29-37) | 29% (23-35) | .1 |